Results 231 to 240 of about 113,897 (352)

Primary Small Cell Neuroendocrine Carcinoma of the Sublingual Gland Treated With Definitive Chemoradiotherapy: A Case Report. [PDF]

open access: yesClin Case Rep
Tokura TA   +10 more
europepmc   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3217-3231, 15 June 2026.
What's new? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken   +20 more
wiley   +1 more source

Rectal large cell neuroendocrine carcinoma. [PDF]

open access: yesOxf Med Case Reports
Drakos PA   +3 more
europepmc   +1 more source

Antiviral regulator TRIM25 as a prognostic marker of better survival in Merkel cell carcinoma: Association with MCPyV status

open access: yesInternational Journal of Cancer, Volume 158, Issue 12, Page 3268-3278, 15 June 2026.
What's new? TRIM25 is known for its role in antiviral immunity and association with poor prognosis in various cancers. This study reveals an association between high TRIM25 expression and Merkel cell polyomavirus positivity in Merkel cell carcinoma.
Klaus W. Fagerstedt   +6 more
wiley   +1 more source

Prognostic and therapeutic roles of specific genotypes through target-gene sequencing on gastroenteropancreatic neuroendocrine carcinoma. [PDF]

open access: yesOncologist
Zhang J   +14 more
europepmc   +1 more source

Tumor‐stromal crosstalk and macrophage enrichment are associated with chemotherapy response in bladder cancer

open access: yesFEBS Open Bio, Volume 16, Issue 6, Page 1197-1212, June 2026.
Chemoresistance in bladder cancer: Macrophage recruitment associated with CXCL1, CXCL5 and CXCL8 expression is characteristic of Gemcitabine/Cisplatin (Gem/Cis) Non‐Responder tumors (right side) while Responder tumors did not show substantial tumor‐stromal crosstalk (left side). All biological icons are attributed to Bioicons: carcinoma, cancerous‐cell‐
Sophie Leypold   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy